

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/003875-2024>

Contract

## **A multi-drug resistant pathogen reference strain and clinical isolate collection**

MEDICINES DISCOVERY CATAPULT SERVICES LIMITED

F03: Contract award notice

Notice identifier: 2024/S 000-003875

Procurement identifier (OCID): ocds-h6vhtk-0425a3

Published 6 February 2024, 1:38pm

### **Section I: Contracting authority**

#### **I.1) Name and addresses**

MEDICINES DISCOVERY CATAPULT SERVICES LIMITED

Block 35g Mereside, Alderley Park

MACCLESFIELD

SK10 4ZF

#### **Email**

[procurement@md.catapult.org.uk](mailto:procurement@md.catapult.org.uk)

#### **Country**

United Kingdom

#### **Region code**

UKD62 - Cheshire East

#### **Companies House**

09928547

**Internet address(es)**

Main address

<https://md.catapult.org.uk/>

**I.4) Type of the contracting authority**

Other type

Drug Discovery / Health

**I.5) Main activity**

Other activity

Drug Discovery / Health

---

## **Section II: Object**

### **II.1) Scope of the procurement**

#### **II.1.1) Title**

A multi-drug resistant pathogen reference strain and clinical isolate collection

#### **II.1.2) Main CPV code**

- 73200000 - Research and development consultancy services

#### **II.1.3) Type of contract**

Services

#### **II.1.4) Short description**

A multi-drug resistant pathogen reference strain and clinical isolate collection representative of pathogens and resistance mechanisms directly aligned to the PACE first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression.

Continued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across *E. coli*, *K. pneumoniae*, *P. aeruginosa*, *A. baumannii* and *S. aureus*. This expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.

#### **II.1.6) Information about lots**

This contract is divided into lots: No

#### **II.1.7) Total value of the procurement (excluding VAT)**

Value excluding VAT: £695,718

### **II.2) Description**

#### **II.2.2) Additional CPV code(s)**

- 73200000 - Research and development consultancy services

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

### **II.2.4) Description of the procurement**

The UKHSA are well positioned to provide the services required by PACE for PACE portfolio funded projects and the wider AMR community. This will include but not be limited to the following:

AST against a well characterised (including phenotypically, whole-genome sequenced with full antibiogram data) set of isolates and strains directly relevant to the PACE funding call, and;

AST data delivered according to industry standards, and;

Provided in an open-access environment, enabling PACE awardees to directly learn from and access the lab capability provided for onward studies, and;

An opportunity to transfer specific isolates to PACE awardee labs for onward studies, and;

The isolate bank will be evolved using the latest surveillance and national reference laboratory data on clinical isolates currently circulating nationally and internationally, and;

UKHSA AMR labs then enable rapid characterisation of new isolates including full antibiogram and whole genome sequencing, and;

A service model that can account for diverse needs of the PACE-funded projects as they arise i.e. variations to SOPs as required and ability to provide rapid surge capacity as and when needed.

### **II.2.5) Award criteria**

Price

### **II.2.11) Information about options**

Options: No

---

## Section IV. Procedure

### IV.1) Description

#### IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

- The procurement falls outside the scope of application of the regulations

Explanation:

Following the voluntary ex ante transparency (VEAT) notice previously published, indicating that Medicines Discovery Catapult, intends to enter into a contract with the UK Health Security Agency (UKHSA) for a multi-drug resistant pathogen reference strain and clinical isolate collection without a call to competition in accordance with the Public Contracts Regulations 2015 ((32.2(b) ii), Medicines Discovery Catapult has now entered into the contract with UKHSA.

The contract is directly aligned to the PACE (Pathways to Antimicrobial Clinical Efficacy) first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression and will allow continued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across *E. coli*, *K. pneumoniae*, *P. aeruginosa*, *A. baumannii* and *S. aureus*.

This expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.

The UKHSA maintains unique capabilities and assets that are part of the country's critical national infrastructure to support this aim, this includes;

The English surveillance programme for antimicrobial utilisation and resistance (ESPAUR), which identifies emergence and trends in key resistance-causing pathogens.

The AMRHAI (antimicrobial resistance and healthcare associated infections) national reference unit, part of the Bacteriology reference department (BRD) - a national and international laboratory reference centre for a bacterial infections.

The isolate bank will be evolved using the latest surveillance and national reference laboratory data on clinical isolates currently circulating nationally and internationally and;

UKHSA AMR labs then enable rapid characterisation of new isolates including full antibiogram and whole genome sequencing.

#### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: Yes

#### **IV.2) Administrative information**

##### **IV.2.1) Previous publication concerning this procedure**

Notice number: [2023/S 000-036804](#)

---

## **Section V. Award of contract**

A contract/lot is awarded: Yes

### **V.2) Award of contract**

#### **V.2.1) Date of conclusion of the contract**

2 January 2024

#### **V.2.2) Information about tenders**

Number of tenders received: 1

The contract has been awarded to a group of economic operators: No

#### **V.2.3) Name and address of the contractor**

UK Health Security Agency

Salisbury

Country

United Kingdom

NUTS code

- UK - United Kingdom

Justification for not providing organisation identifier

Not on any register

The contractor is an SME

No

#### **V.2.4) Information on value of contract/lot (excluding VAT)**

Initial estimated total value of the contract/lot: £695,718

Total value of the contract/lot: £695,718

---

## **Section VI. Complementary information**

### **VI.4) Procedures for review**

#### **VI.4.1) Review body**

Medicines Discovery Catapult

Macclesfield

SK10 4ZF

Country

United Kingdom